Analysts cut price targets and reduced their estimates for azetukalner’s psychiatric commercial opportunity after Xenon Pharmaceuticals disclosed an enrollment pause in its Phase 3 depression trials — XENE shares fell as much as 27.6%.
NEW YORK, Sept. 22, 2026 /PRNewswire/ — A roughly 22% after-hours decline in Xenon Pharmaceuticals Inc. (NASDAQ: XENE) widened to more than 25% in the trading that followed and ultimately closed down 30.7% after the Company disclosed that it had paused new patient enrollment in its Phase 3 azetukalner trials for major depressive disorder and bipolar depression. Shareholders who lost money on XENE are encouraged to submit their losses for review now. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt.
The pause followed a safety review, conducted in consultation with the Data Safety Monitoring Board, of neuropsychiatric adverse events including confusion, speech difficulties, coordination problems, and a small number of psychotic episodes. Those events had not appeared in the earlier Phase 2 X-NOVA study.
The analyst response was immediate. Needham removed all major depressive disorder and bipolar disorder sales projections from its valuation of the Company, and Deutsche Bank downgraded XENE to Hold. Price targets were cut across the Street. The Company has said already-randomized patients remain on study and that X-NOVA2 will unblind at approximately 360 of 450 planned patients, with topline data expected in the first quarter of 2027.
Investors who purchased XENE shares and suffered a loss are encouraged to have your XENE losses evaluated at no cost. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt.
WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the XENE Investigation
Q: How much did XENE stock drop?A: Shares fell approximately 22% in after-hours trading and widened to more than 25% in the trading that followed and ultimately closed down 30.7%, after the Company disclosed a pause in new patient enrollment in its Phase 3 azetukalner trials for major depressive disorder and bipolar depression. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek recovery.
Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether Xenon Pharmaceuticals Inc. made materially false or misleading statements regarding the safety profile and clinical development of azetukalner in its psychiatry program. When the Company disclosed the enrollment pause following a review of neuropsychiatric adverse events, the stock price declined sharply.
Q: Who is eligible to participate in the XENE investigation?A: Investors who purchased XENE stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.
Q: What do XENE investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my XENE shares — can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought XENE and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.
Q: How long will the investigation take to resolve?A: The timeline depends on the facts developed during the investigation, the court schedule, and case developments, including whether legal action is later pursued, dismissed, resolved, or litigated further.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com
Tel: (888) SueWallSt
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/xenon-pharmaceuticals-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-xenon-pharmaceuticals-xene-302886738.html
SOURCE SueWallSt.com
